May 24, 2016 / 3:16 PM / a year ago

BRIEF-Abbvie IL-23 Inhibitor Risankizumab induces remission in Phase II Study

May 24 (Reuters) - Abbvie Inc

* IL-23 inhibitor risankizumab induces remission in phase ii study in patients with moderate-to-severe crohn's disease

* Risankizumab was shown to be more effective than placebo in patients with moderately-to-severely active crohn's disease

* Risankizumab achieved higher rates of clinical response than placebo with nearly twice as many patients achieving clinical response

* After 12 weeks, 24% and 37% of patients achieved clinical remission with 200 mg and 600 mg risankizumab, compared with 15% receiving placebo

* Trial is ongoing and will evaluate patients up to 52 weeks

* Risankizumab was well tolerated in trial, with numerically fewer severe or serious adverse events in risankizumab treated patients versus placebo Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below